Dataset opportunity
Phenox — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Phenox, usable for Diagnostic AI and Computer Vision.
Score
61.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market = $2.1 billion in 2025, CAGR 23.9%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 🧑💻Hiring a data role
Recruiting Senior Clinical Project Manager for study milestone delivery
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Phenox holds a significant Medical Imaging Dataset, comprised of various image modalities sourced directly from its clinical studies and business operations. This collection of medical_records and proprietary images is curated and directly usable for developing and validating high-performance Diagnostic AI algorithms, with its primary value rooted in the direct link to real-world patient outcomes.
The global AI in Medical Imaging market was valued at $2.1 billion in 2025 and is projected to expand at a 23.9% CAGR, demonstrating immense growth and demand. [8] While access is governed by strict GDPR, clinical trial regulations, and requires group-level approval from Wallaby Medical, the rarity and clinical relevance of this data make it a highly valuable asset for AI developers seeking a competitive edge in this rapidly growing market. ⚠ Diligence (valuable data, access to negotiate): Medical data subject to strict GDPR and clinical trial regulatory compliance; Subsidiary of Wallaby Medical; requires group-level data governance approval; Data access restricted by specific patient consent forms from clinical studies · corporate: acquired of Wallaby Medical.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Evidence confirms Phenox possesses a proprietary dataset covering over 20,000 patients treated for aneurysms with its specialized medical devices. This high-volume, real-world data, including clinical trial results and angiographic follow-ups, is a critical asset for developing and validating next-generation diagnostic AI models. For medical AI firms, this dataset offers a rare opportunity to train algorithms on a large, specific patient cohort, accelerating entry into the rapidly growing AI in Medical Imaging market, projected to reach $2.1 billion by 2025.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
High buyer demand is driven by the rapid expansion of the AI in Medical Imaging market, which is growing at a 23.9% CAGR, creating a strong need for high-quality, clinically-validated training data. [8]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, acquired of Wallaby Medical
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence45
acquired of Wallaby Medical
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Phenox is a good target as it develops and manufactures physical neurovascular medical devices, with any resulting imaging data being a by-product of its core operational business, not its primary product for sale. Issues: The company was acquired by Wallaby Medical in 2022, making it part of a larger organization, which could complicate decision-making. [1, 5, 17]
- Deep Qualification90
⚠ needs review — Phenox is a medical device manufacturer whose clinical trials generate a valuable, proprietary medical imaging dataset; however, access is heavily restricted by GDPR, clinical trial regulations, and patient consent. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence points to a structured dataset from a randomized clinical trial, providing high-quality, longitudinal patient outcomes essential for training predictive diagnostic models.
Image collection
The collection includes angiographic follow-up images (DSA) from a multicenter study, offering the specific medical imaging data required to refine computer vision algorithms for aneurysm treatment analysis.
business_records
These records confirm a large-scale, global dataset from over 20,000 patients, demonstrating a significant volume of real-world evidence that is highly sought after for building robust and generalizable AI applications.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Phenox Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $2.1 billion in 2025, CAGR 23.9% (source: Global Market Insights). [8]. Investment score 61.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Vesalio — Medical Imaging Dataset Opportunity
View opportunity →healthcarePsyonic — Medical Imaging Dataset Opportunity
View opportunity →healthcareMed X Press — Inspection Reports Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read
- Your Expertise is Gold for AI3 min read